Syngene International (BOM:539268) Long-Term Capital Lease Obligation : ₹3,651 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Syngene International Long-Term Capital Lease Obligation?

Syngene International's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹3,651 Mil.

Syngene International's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (₹2,755 Mil) to Dec. 2023 (₹0 Mil) but then increased from Dec. 2023 (₹0 Mil) to Mar. 2024 (₹3,651 Mil).

Syngene International's annual Long-Term Capital Lease Obligation increased from Mar. 2022 (₹2,102 Mil) to Mar. 2023 (₹2,142 Mil) and increased from Mar. 2023 (₹2,142 Mil) to Mar. 2024 (₹3,651 Mil).

Syngene International Long-Term Capital Lease Obligation Historical Data

The historical data trend for Syngene International's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syngene International Long-Term Capital Lease Obligation Chart

Syngene International Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

812.00

1,052.00

2,102.00

2,142.00

3,651.00

Syngene International Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															2,142.00	-	2,755.00	-	3,651.00

Syngene International (BOM:539268) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Syngene International Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Syngene International's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Syngene International (BOM:539268) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syngene International Ltd (BOM:539268) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SYNGENE:India

Address

Jigani Link Road, Biocon SEZ, Biocon Park, Plot No. 2 and 3, IV Phase, Bommasandra Industrial Area, Bangalore, KA, IND, 560 099

Website

https://www.syngeneintl.com

Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the US. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.

Syngene International (BOM:539268) Headlines

No Headlines